Study signals “real paradigm shift” in care resulting from the world’s first FDA-cleared, 30-minute, molecular point-of-care platform for the detection of chlamydia and gonorrhea
Latest FDA clearance establishes binx as the fastest dual-gender rapid test-and-treat platform for chlamydia and gonorrhea
COVID-19 pandemic has created growing backlog of millions in need of routine STI testing
binx health was featured in Fortune Magazine highlighting the io platform as not only the first and fastest FDA-cleared molecular point-of-care diagnostic for the detection of chlamydia and gonorrhea, but…
binx offers first FDA 510(k) cleared molecular point-of-care solution for test and treat of sexually-transmitted infections in a single visit
binx health, the pioneer in anywhere, anytime testing for women’s health, today announced that Jeffrey Luber, president and CEO is scheduled to present on Thursday, November 21, 2019 at 11:00…
binx FDA-cleared platform already impacting human health—poised to transform care for millions
binx io enables first-ever “test-and-treat” paradigm with sample to answer in 30 minutes for the two most tested-for sexually transmitted infections (STIs)
binx health, the pioneer in anywhere care in women’s health, today announced the appointment of Dr. Gail Marcus to its Board of Directors.
binx health announces second FDA 510(K) clearance of its molecular point-of-care infectious disease platform.
